In 43 adults who finished a six-month trial, a multi-ingredient powder lined up with wider arm-artery flow and lower systolic pressure

What the research found

European Heart Journal Open published a randomized, double-blind, placebo-controlled trial, DOI 10.1093/ehjopen/oeag157. Lifespan.io covered it on 6 November 2026. Charles Piercy, Christian Heiss, and colleagues at the University of Surrey assigned 61 generally healthy nonsmoking adults to a once-daily multi-ingredient powder or a matching placebo for six months (33 versus 28). Forty-three finished the primary analysis (24 versus 19). The powder is sold as NOVOS Core. Lifespan.io reports that NOVOS supplied the product and the placebo and helped fund the study. At six months, flow-mediated dilation rose 2.6 percentage points on the powder and fell 0.1 on placebo, an adjusted difference of +2.9 points (95 percent CI 2.1 to 3.8). One hour after the first dose the adjusted difference was +3.9 points (95 percent CI 2.7 to 5.1). Pulse-wave velocity differed by -1.18 m/s at six months (95 percent CI -2.00 to -0.36). Systolic pressure differed by -6.1 mmHg (95 percent CI -10.9 to -1.3). Lipids did not differ. Estimated 10-year risk (SCORE2 or SCORE2-OP) differed by -0.45 points (95 percent CI -0.86 to -0.03), mostly from the pressure change. The trial registration on the preprint record is NCT06145087. Lifespan.io also reports that the control group was older at enrollment, about 60 versus 53. Nearly a third of people did not finish. The study was not built to count heart attacks or strokes. Flow-mediated dilation is a vessel measurement, not a clinical outcome. This is not a reason to buy the powder. DOI 10.1093/ehjopen/oeag157. Not medical advice. Not a treatment for heart disease.

Evidence level: Clinical trial. This is among the stronger kinds of evidence, but one study rarely settles a question.

Read the original at European Heart Journal Open